Neuronetics Closes $34 Million in Series F Financing with GE Ventures and Current Investors Additional investment will help fund the company’s growing commercial development and plans to initiate a new clinical study of NeuroStar TMS Therapy in adolescent patients...
For Wall Street Journal coverage of this financing, click here. Intarcia Therapeutics Closes Novel $225 Million Synthetic Royalty Financing with Equity Conversion Option at $5.5 Billion Valuation – Company secures $225M financing in exchange for 1.5% of future...
Oxford Immunotec Announces CE Mark Approval for T-SPOT.CMV Test Product to be featured at a symposium at the European Congress of Clinical Microbiology and Infectious Disease OXFORD, UK and MARLBOROUGH, MA, April 27th, 2015 (GLOBE NEWSWIRE) – Oxford Immunotec Global...
Banner Health to Offer iRhythm ZIO Service for Continuous Cardiac Monitoring SAN FRANCISCO – April 21, 2015 – iRhythm Technologies, Inc., a leading digital healthcare solutions company focusing on the advancement of cardiac care, announced today that Banner Health,...
Versartis Initiates Phase 2/3 Trial of VRS-317 in Japan for Children With Growth Hormone Deficiency MENLO PARK, Calif., April 13, 2015 (GLOBE NEWSWIRE) — Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel,...
Recent Comments